Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Pashirova, Tatiana N.; Zueva, Irina V.; Петров, К. А.; Лукашенко, С. С.; Nizameev, Irek R.; Kulik, Natalya V.; Voloshina, A. D.; Almásy, László; Kadirov, Marsil K.; Masson, Patrick; Souto, Eliana B.; Zakharova, L. Ya.; Sinyashin, Оleg G.

doi:10.1016/j.colsurfb.2018.07.049

Cited by 72 publications

(57 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This section details the most commonly used methods for the production of each type of nanoparticles illustrated in Figure 4. Lipid nanoparticles can be of different types (e.g., liposomes [13][14][15][16], nanoemulsions [14,17,18], solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) [19][20][21][22][23][24]), each produced from very different lipids (e.g., phospholipids, synthetic oils, essential oils from plants, fatty acids, di-, mono-, and triglycerides, cholesterol), commonly resembling those existing in the human body and also in food. Due to their lipid composition, these particles are usually referred to as biocompatible, biodegradable and are generally recognized as safe [25][26][27].…”

Section: Production Methods Of Clinically Compliant Nanopharmaceuticsmentioning

confidence: 99%

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

et al. 2020

Self Cite

View full text Add to dashboard Cite

Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations-nanopharmaceutics-have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing "Nanopharmaceutics: Part I-Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU" has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.Nanomaterials 2020, 10, 455 2 of 16 funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1). Nanomaterials 2020, 10, x FOR PEER REVIEW 2 of 17European Commission aims to lead innovation towards the development of these nanopharmaceutics by launching several funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1).

show abstract

Section: Production Methods Of Clinically Compliant Nanopharmaceuticsmentioning

confidence: 99%

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Liposomes are concentric phospholipid bilayers enclosing an aqueous core, making them suitable to load hydrophilic, lipophilic, and amphiphilic compounds [77][78][79]. Their use has been described for a set of administration routes, among which the topical delivery of APIs has been successfully exploited [80].…”

Section: Liposomesmentioning

confidence: 99%

Nanomaterials for Skin Delivery of Cosmeceuticals and Pharmaceuticals

et al. 2020

Self Cite

View full text Add to dashboard Cite

Skin aging is described as dermatologic changes either naturally occurring over the course of years or as the result of the exposure to environmental factors (e.g., chemical products, pollution, infrared and ultraviolet radiations). The production of collagen and elastin, the main structural proteins responsible for skin strength and elasticity, is reduced during aging, while their role in skin rejuvenation can trigger a wrinkle reversing effect. Elasticity loss, wrinkles, dry skin, and thinning are some of the signs that can be associated with skin aging. To overcome skin aging, many strategies using natural and synthetic ingredients are being developed aiming to reduce the signs of aging and/or to treat age-related skin problems (e.g., spots, hyper- or hypopigmentation). Among the different approaches in tissue regeneration, the use of nanomaterials loaded with cosmeceuticals (e.g., phytochemicals, vitamins, hyaluronic acid, and growth factors) has become an interesting alternative. Based on their bioactivities and using different nanoformulations as efficient delivery systems, several cosmeceutical and pharmaceutical products are now available on the market aiming to mitigate the signs of aged skin. This manuscript discusses the state of the art of nanomaterials commonly used for topical administration of active ingredients formulated in nanopharmaceuticals and nanocosmeceuticals for skin anti-aging.

show abstract

“…In particular, cationic lipids by themselves or in combination with other lipids or assemblies can yield interesting microenvironments to accommodate a variety of bioactive molecules such as drugs, antigens, peptides, nucleic acids, etc. [30][31][32][33][34][35][36][37]. The nanometric size and positive charge impart desirable properties for the cationic assemblies after injection via parenteral route in vivo.…”

Section: Introductionmentioning

confidence: 99%

“…The nanometric size and positive charge impart desirable properties for the cationic assemblies after injection via parenteral route in vivo. Good instances are the direct action at the lymph nodes for stimulation of dendritic cells for vaccines [9,22,31,[34][35][36][37], and the penetration of nasal mucosae to overcome the blood brain barrier releasing drugs into the brain [33]. Other important applications relate to the antimicrobial properties of a variety of cationic assemblies either by themselves such as cationic bilayers or in effective combinations with other antimicrobials such as antibiotics, polymers or peptides [7,23,[38][39][40][41][42][43][44][45].…”

Section: Introductionmentioning

confidence: 99%

Biomimetic Nanomaterials from the Assembly of Polymers, Lipids, and Surfactants

Carmona-Ribeiro¹

2019

Surfactants and Detergents

View full text Add to dashboard Cite

Nanostructured materials require evaluation at a molecular level to become controllable and useful in drug and vaccine delivery. Over the years self-assembled nanomaterials such as nanoparticles and thin films have been prepared, characterized and used for biomedical applications. In this review meaningful examples of biomimetic nanomaterials and their construction based on intermolecular interactions such as the electrostatic attraction or the hydrophobic effect will be discussed. Emphasis will be placed on the interactions between polymers, lipids, surfactants and surfaces leading to bioactive supramolecular assemblies such as nanoparticles and coatings. Among the important applications of the self-assembled nanostructures and films to be reviewed are their antimicrobial effect and their adjuvant activity for vaccine delivery.

show abstract

Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Cited by 72 publications

References 75 publications

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

Nanomaterials for Skin Delivery of Cosmeceuticals and Pharmaceuticals

Biomimetic Nanomaterials from the Assembly of Polymers, Lipids, and Surfactants

Contact Info

Product

Resources

About